Numab Therapeutics has raised a total of 22 million Swiss francs as part of a Series B financing round, as detailed in a press release. The new investors include the Chinese company Sunshine Guojian Pharmaceutical, the Japanese pharmaceutical firm Eisai as well as the venture capital company Mitsubishi UFJ Capital. Last year, Numab Therapeutics already agreed other partnerships with both Guojian Pharmaceutical and Eisai. Further investors include the former CEO of Novartis, Daniel Vasella, who in 2019 joined the Supervisory Board of Numab Therapeutics, which is based in Wädenswil.
Numab Therapeutics develops multi-specific antibodies in the areas of immuno-oncology and immunology. The fresh capital is to be used to advance the development of product candidates. The company is planning, for example, to start the first round of clinical trials by the end of this year for its oncological program ND021.
Related news
Meet with an expansion expert
Our services are free of charge and include:
- Introduction to key contacts in industry, academia, and government
- Advice on regulatory framework, taxes, labor, market, and setting up a company
- Custom-made fact-finding visits, including office and co-working space